US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

Johnson & Johnson

JNJNYSE

177.24

USD
+0.23
(+0.13%)
Market Closed
25.80P/E
17Forward P/E
1.29P/E to S&P500
463.390BMarket CAP
2.47%Div Yield
Upcoming Earnings
24 Jan
Shares Short
11/15/22
12.66M
Short % of Float
0.48%
Short % of Shares Outs.
0.48%
% Held by Insiders
0.09%
% Held by Institutions
70.62%
Beta
0.57
PEG Ratio
4.82
52w. high/low
186.69/155.72
Avg. Daily Volume
7.00M
Return %
Stock
S&P 500
1 year
10.84
(12.95)
3 years
28.84
27.86
5 years
28.54
54.69
Scale: |
High
Low
68.75
59.72
72.76
52.06
65.41
46.25
66.20
56.86
68.05
57.50
72.74
61.71
95.99
70.30
109.49
86.09
106.50
81.79
126.07
94.28
144.35
110.76
148.99
118.62
147.84
125.00
157.66
109.16
179.92
151.47
186.69
155.72
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
18.14
21.20
22.67
22.43
22.49
23.87
24.19
25.28
26.71
25.43
26.56
28.50
30.64
31.17
31.37
35.63
54.57
Earnings per share
3.76
3.67
4.61
4.44
4.87
3.55
3.91
4.90
5.86
5.59
6.11
0.48
5.75
5.74
5.59
7.93
11.07
FCF per share
3.92
4.14
4.23
5.15
5.11
4.19
4.49
4.90
5.30
5.74
5.74
6.63
6.96
7.57
7.67
7.51
6.75
Dividends per share
1.45
1.62
1.79
1.93
2.12
2.26
2.38
2.58
2.79
2.97
3.19
3.33
3.57
3.77
3.98
4.19
4.38
CAPEX per share
0.93
1.15
1.09
0.86
0.87
1.06
1.06
1.27
1.33
1.26
1.19
1.22
1.38
1.33
1.27
1.39
1.46
Book Value per sh.
13.38
15.03
15.12
18.33
20.66
20.95
23.33
26.25
25.06
25.82
26.02
22.43
22.44
22.59
24.04
28.12
28.49
Comm.Shares outs.
2,940
2,882
2,812
2,760
2,738
2,724
2,778
2,821
2,783
2,755
2,707
2,683
2,662
2,633
2,633
2,632
2,629
Avg. annual P/E ratio
16.5
17.4
14.0
13.9
13.0
18.9
17.2
17.4
17.1
20.3
21.2
267.4
23.1
23.5
29.6
21.6
25.8
P/E to S&P500
0.9
1.0
0.7
0.7
0.8
1.3
1.2
1.0
0.9
0.9
0.9
11.3
0.9
1.0
1.0
1.1
1.3
Avg. annual div. yield
2.3%
2.5%
2.8%
3.1%
3.3%
3.4%
3.6%
3.0%
2.8%
2.6%
2.5%
2.6%
2.7%
2.8%
2.4%
2.4%
2.6%
Revenue (m)
53,324
61,095
63,747
61,897
61,587
65,030
67,224
71,312
74,331
70,074
71,890
76,450
81,581
82,059
82,584
93,775
143,487
Operating margin
25.7%
24.9%
25.4%
26.9%
26.8%
24.8%
25.3%
26.6%
28.4%
26.1%
29.4%
25.0%
26.0%
25.6%
24.1%
26.2%
24.9%
Depreciation (m)
2,177
2,777
2,832
2,774
2,939
3,158
3,666
4,104
3,895
3,746
3,754
5,642
6,929
7,009
7,231
7,390
7,041
Net profit (m)
11,053
10,576
12,949
12,266
13,334
9,672
10,853
13,831
16,323
15,409
16,540
1,300
15,297
15,119
14,714
20,878
29,120
Income tax rate
24.2%
20.4%
23.5%
22.1%
21.3%
21.8%
23.7%
10.6%
20.6%
19.7%
16.5%
92.6%
15.0%
12.7%
10.8%
8.3%
12.4%
Net profit margin
20.7%
17.3%
20.3%
19.8%
21.7%
14.9%
16.1%
19.4%
22.0%
22.0%
23.0%
1.7%
18.8%
18.4%
17.8%
22.3%
20.3%
Working capital (m)
3,814
10,108
13,525
17,810
24,235
31,505
21,854
30,732
34,226
32,463
38,745
12,551
14,803
9,310
8,744
15,753
19,693
Long-term debt (m)
2,014
7,074
8,120
8,223
9,156
12,969
11,489
13,328
15,122
12,857
22,442
30,675
27,684
26,494
32,635
29,985
27,603
Equity (m)
39,318
43,319
42,511
50,588
56,579
57,080
64,826
74,053
69,752
71,150
70,418
60,160
59,752
59,471
63,278
74,023
74,599
ROIC
21.5%
17.3%
20.7%
17.3%
17.2%
11.1%
11.5%
13.3%
15.8%
15.0%
14.9%
1.1%
13.3%
12.6%
11.2%
15.4%
23.2%
Return on capital
20.7%
16.4%
20.4%
17.1%
16.9%
11.4%
12.1%
12.0%
16.1%
14.8%
14.5%
11.8%
12.4%
11.2%
9.5%
12.6%
19.6%
Return on equity
28.1%
24.4%
30.5%
24.2%
23.6%
16.9%
16.7%
18.7%
23.4%
21.7%
23.5%
2.2%
25.6%
25.4%
23.3%
28.2%
39.0%
Plowback ratio
61.4%
55.8%
61.2%
56.6%
56.5%
36.4%
39.1%
47.3%
52.4%
47.0%
47.9%
(587.9)%
37.9%
34.4%
28.8%
47.2%
39.9%
Div.&Repurch./FCF
85.6%
73.0%
98.1%
52.5%
61.4%
76.1%
156.7%
78.3%
100.9%
85.1%
113.2%
86.1%
82.9%
83.7%
67.9%
73.3%
97.1%
Capital Structure
27 Oct · 2022 |
All numbers in millions
Total liabilities
$ 100,525
Total assets
$ 175,124
Long-term debt
$ 27,603
Cash and equiv.
$ 11,355
Goodwill
$ 33,383
Retained earnings
$ 127,917
Common stock
2,630
Enterprise Value
$ 479,638
Working Capital
Currency: USD, in millions
2019
2021
2022
Cash & Investments
19,287
25,185
31,608
Receivables
14,481
13,576
15,283
Inventory
9,020
9,344
10,387
Other
2,486
11,616
12,687
Current assets
45,274
51,237
60,979
Acc. Payable
8,544
9,505
11,055
Debt due
1,202
2,631
3,766
Other
26,218
30,357
30,405
Current liabilities
35,964
42,493
45,226
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
13.55%
5.37%
3.89%
Cash flow
(2.13)%
2.74%
5.38%
Earnings
41.89%
278.69%
118.87%
Dividends
5.26%
5.39%
5.86%
Book value
16.98%
5.56%
1.90%
Insider Trading
Type
Shares
Date
Taubert Jennifer L
Exempt
76,923
11/22/22
Taubert Jennifer L
Sale
76,923
11/22/22
Taubert Jennifer L
Exempt
76,923
11/22/22
Decker Robert J
Exempt
16,928
11/18/22
Decker Robert J
Sale
16,928
11/18/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2021
20,691
18,336
21,082
22,475
82,584
2022
22,321
23,312
23,338
24,804
93,775
2023
23,426
24,020
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
2.20
1.38
1.35
0.66
5.59
2022
2.35
2.39
1.39
1.80
7.93
2023
1.96
1.83
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
0.95
1.01
1.01
1.01
3.98
2022
1.01
1.06
1.06
1.06
4.19
2023
1.06
1.13
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—General
CEO:
Mr. Alex Gorsky
Full-time employees:
141,700
City:
New Brunswick
Address:
1 Johnson And Johnson Plz
IPO:
Sep 25, 1944
Website:
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Recent News
· 1 Nov, 2022 · The Wall Street Journal
· 18 Oct, 2022 · The Wall Street Journal
· 28 Sep, 2022 · The Wall Street Journal
· 19 Jul, 2022 · The Wall Street Journal
· 24 May, 2022 · The Wall Street Journal
· 11 May, 2022 · The Wall Street Journal
· 5 May, 2022 · The Wall Street Journal
· 26 Apr, 2022 · The Wall Street Journal
· 19 Apr, 2022 · The Wall Street Journal
· 18 Apr, 2022 · The Wall Street Journal
· 30 Mar, 2022 · The Wall Street Journal
· 2 Feb, 2022 · The Wall Street Journal
· 25 Jan, 2022 · The Wall Street Journal
· 17 Dec, 2021 · The Wall Street Journal
· 6 Dec, 2021 · The Wall Street Journal
· 26 Nov, 2021 · The Wall Street Journal
· 21 Nov, 2021 · The Wall Street Journal
· 12 Nov, 2021 · The Wall Street Journal
· 12 Nov, 2021 · The Wall Street Journal